First infection by all four non-severe acute respiratory syndrome human coronaviruses takes place during childhood by unknown
RESEARCH ARTICLE Open Access
First infection by all four non-severe acute
respiratory syndrome human coronaviruses takes
place during childhood
Weimin Zhou, Wen Wang, Huijuan Wang, Roujian Lu and Wenjie Tan*
Abstract
Background: Non-severe acute respiratory syndrome (non-SARS)-related human coronaviruses (HCoVs), including
HCoV-229E, -HKU1, -NL63, and -OC43, have been detected in respiratory tract samples from children and adults.
However, the natural prevalence of antibodies against these viruses in serum among population is unknown.
Methods: To measure antibodies to the spike (S) protein of the four common non-SARS HCoVs, recombinant
S proteins of the four HCoVs were expressed and characterised in 293 T cell. An S-protein-based indirect
immunofluorescence assay (IFA) was then developed to detect anti-S IgG and IgM for the four individual HCoVs
and applied to serum samples from a general asymptomatic population (218 children and 576 adults) in Beijing.
Results: Of 794 blood samples tested, only 29 (3.65%) were negative for anti-S IgG. The seropositivity of the four
anti-S IgG antibodies was >70% within the general population. The majority of seroconversions to four-HCoV
positivity first occurred in children. Both S-IgG and S-IgM antibodies were detectable among children and increased
with age, reaching a plateau at 6 years of age. However, no anti-S IgM was detected in healthy adults.
Conclusion: Large proportions of children and adults in Beijing have evidence of anti-S IgG against four the HCoVs,
and first infections by all four non-SARS HCoVs takes place during childhood.
Keywords: Human coronavirus, Spike protein, Indirect immunofluorescence assay, Antibody
Background
Coronaviruses are positive-sense, single-stranded RNA vi-
ruses found in humans and a wide variety of animals [1].
In humans, four respiratory coronaviruses, namely human
coronavirus (HCoV) -229E [2], -OC43 [3], -NL63 [4], and
-HKU1 [5], are endemic worldwide. These four common
strains cause diseases from mild, febrile upper respiratory
tract illnesses to severe outcomes, such as croup, bron-
chiolitis, and pneumonia, and attribute to about 10% of all
upper and lower respiratory tract infections in hospitalised
children [1,6]. In 2003, a previously unknown coronavirus
caused an outbreak of severe acute respiratory syndrome
(SARS) in humans [7,8]. More recently, the novel beta-
coronavirus species HCoV-EMC was identified from a
man with pneumonia in Saudi Arabia [9].
Coronaviruses are phenotypically and genotypically di-
verse [6,10]. All coronaviruses possess a common genome
organisation in which the replicase gene encompassing
the 5’ two-thirds of the genome is comprised of two over-
lapping open reading frames, ORF1a and ORF1b. The
structural gene region, which covers the 3’ third of the
genome, encodes the canonical set of structural protein
genes in the order 5’-spike (S)→ envelope (E)→mem-
brane (M)→ nucleocapsid (N)-3’ [1,10]. The S proteins is
the most immunodominant CoV protein [1,6,10].
The most common method for diagnosing HCoV infec-
tion is reverse transcription polymerase chain reaction
(RT-PCR) or real-time RT-PCR using RNA extracted from
respiratory tract samples, such as nasopharyngeal aspirates
[6,11,12]. On the other hand, serological assays for detec-
tion of antibody to HCoV are more complex to establish
[1,6]. However, determining the levels of immunoglobulin
M (IgM) and immunoglobulin G (IgG) antibodies in ap-
propriate serum or plasma samples allows the researcher
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to define the point in time of primary infection as well as
exposure rates; seroepidemiological studies are also im-
portant tools for HCoV infection diagnosis and research
[6,13-17]. Previous reports have indicated that immu-
nofluorescence assays (IFAs) for the detection of sero-
conversion with IgG antibodies against the main structural
(N and S) proteins of SARS-CoV are useful for the diagno-
sis of acute SARS-CoV infection [18,19]. Little is currently
known about the prevalence of anti-S antibodies specific
for non-SARS HCoV infection among children and adults.
We propose that an IFA for the detection of IgG against
structural (N and S) proteins of non-SARS HCoV may be
suitable for seroepidemiological studies.
To expand the epidemiological knowledge of four non-
SARS-related endemic HCoVs in China, we expressed
S proteins in a eukaryotic system and established an IFA
for the detection of IgG or IgM antibodies against these
four viruses. We used this system to determine the preva-
lence of anti-S IgG and IgM antibodies against HCoVs
among a general population in Beijing.
Methods
Study population
794 serum samples were obtained from a general asymp-
tomatic population (6 months to 75 years of age) who vis-
ited hospitals for medical examinations or vaccinations in
Beijing from 1999 to 2011. All aspects of this study were
performed in accordance with the national ethics regula-
tions and approved by the Institutional Review Boards of
the Centre for Disease Control and Prevention of China
and the Ethics Committee of Peking Union Medical
College Hospital. Participants received written informa-
tion regarding the purpose of the study and of their right
to confidentiality. Written informed consent was obtained
from all participants or their guardians.
Construction of HCoV-S expression plasmids
S-protein-coding gene optimisation was conducted
and oligonucleotides synthesised (Qingke Bio-Tech
Engineering Service Co., Ltd., Beijing) according to the
S-protein sequences of four non-SARS-related endemic
HCoVs in GenBank (229ENC_002645, OC43NC_005147,
HKU1NC_006577, and NL63NC_005831). The leader
sequence of the original gene was removed and replaced
by a human TPA leader sequence (1–21 aa) at the
N-terminal of the S fragment. Artificially synthesised
S fragments of HCoV-OC43, -229E, -HKU1, and -NL63
were cloned into the eukaryotic expression plasmid pVRC
(a gift from Dr. Gary Nabel, NIH, USA) and named
pVRC-229E-S, -OC43-S, -HKU1-S, and -NL63-S, respect-
ively (Figure 1A). The plasmid pVRC-8304 (from Dr. Gary
Nabel, NIH, USA) [20], in which the S-protein-coding
gene of SARS-CoV was constructed and used as a DNA
vaccine, was used as the control.
Preparation of mouse anti-S sera by DNA immunisation
Female BALB/c (H-2d) mice between 6 and 8 weeks of
age (Animal Care Centre, Chinese Academy of Medical
Science, Beijing, China) were randomly assigned to four
groups. In accordance with the Institutional Animal
Care and Use Committee (IACUC)-approved protocol,
all mice were immunised at weeks 0, 3, and 6 and bled
at week 8. The mice were anaesthetised and primed with
the above S-expression plasmid using intradermal injec-
tion into the lower dorsal side (10 μg/30 μL). Gene de-
livery using in vivo electroporation was performed as
described previously [21]. Serum samples were collected
2 weeks after the last vaccination, and the pooled anti-S
serum against individual HCoVs was stored at −70°C.
Western blotting
293FT cells were transfected with individual S-expression
plasmids using Lipofectinamine2000 reagent (Invitrogen
Company). At 36 h post-transfection, the cells were lysed
in ice-cold RIPA buffer (50 mM Tris–HCl [pH 7.5],
150 mM NaCl, 1% Triton X-100, 0.1% SDS, and 0.5% so-
dium deoxycholate) supplemented with a protease inhibi-
tor mixture (Sigma, St. Louis, MO). The lysates were kept
on ice for 10 min, centrifuged, and resolved by SDS/PAGE
in a 6% polyacrylamide gel. The proteins were transferred
to a nitrocellulose membrane, blocked with 5% skim
milk in PBS for 2 h, and incubated for 8 h at 4°C with
anti-S mouse polyclonal antibody diluted to 1:50 in
blocking buffer. The membrane was washed in PBS
containing Tween 20 (0.1%) and incubated for 1 h with
horseradish peroxidase-conjugated anti-mouse secondary
antibody (Pierce, Rockford, IL) diluted to 1:5000. The
membrane was washed and the proteins were visualised
with SuperSignal Chemiluminescence Substrate (Pierce).
Indirect IFA
An IFA was used to detect HCoV S glycoprotein expres-
sion in 293 T cells. Briefly, 293 T cells seeded on glass
slides were transfected with pVRC-229E-S, -OC43-S,
-HKU1-S, and -NL63-S plasmids, respectively. After a
36-h incubation at 37°C in 5% CO2, the cells were fixed
in 2% paraformaldehyde and blocked in 5% normal goat
blood serum in 1% Triton-X-100 PBS. The infected cells
were incubated with anti-S mouse serum (1:500) for 1 h,
and then incubated with FITC-labelled goat anti-mouse
IgG (H + L; Zhongahan Co., Beijing, China) for 30 min.
Positive foci were identified by fluorescence microscopy
(Nikon, Tokyo, Japan) after Evans blue duplicate staining.
For serum anti-S IgG or IgM detection using IFA, an
individual HCoV S glycoprotein expression plasmid was
used to transfect the 293 FT cells in the 75-cm2 flask.
Forty-eight hours later, the transfected cells were washed
twice with PBS and then dripped onto the slide. The
cells were fixed using 4% paraformaldehyde for 10 min,
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then permeabilised using 0.2% TritonX-100 and washed
three times with PBS. The anti-S-specific antibodies in
sera (diluted to 1:20) were quantified using 1:100-diluted
FITC-labelled sheep anti-human IgG (H + L; Zhongahan
Co., Beijing, China) or 1:40-diluted FITC-labelled anti-
human IgM (μ-chain-specific), and the slide was viewed
under an inverted fluorescence microscope (Olympus,
Tokyo, Japan). Serum samples that reacted with HCoV
S protein at a dilution of >1:20 were considered positive
for anti-S antibodies when duplicate or triple test was con-
sistent. Furthermore, we confirmed that non-transfected
293 T cells or those transfected with the control plasmid
(pVRC8304, which expresses the S protein of SARS-
CoV) did not react with the human serum samples
tested.
Statistical analysis
Statistical analysis was performed using the Statistic
Package for Social Science(SPSS) statistic 17 package
with χ2-test and Fisher’s exact test. Differences between
the mean values of each group were considered signifi-
cant at p < 0.05 when assessed using Tukey’s test.
Results
Population characteristics
The demographic characteristics of the study subjects
are summarised in Table 1. Of 794 patients subjects
studied, 215 (27.08%) were infants or children <14 years
of age; 457 (57.55%) were male. The average age of the
adults and children was 28.75 ± 17.79 years. The major-
ity of patients in the child population were 1 to 3 years
of age (n = 134, 61.47%), and the majority of adults were
31 to 50 years of age (n = 363, 63.0%).
Construction and characterisation of HCoV-S expression
plasmids
The structures of the S-fragments of individual HCoV
expression constructs used in this study are summarised
in Figure 1A. Expression of the HCoV S proteins was
confirmed by western blotting (Figure 1B). The seg-
ments were detected by anti-S mouse serum derived from
DNA vaccination with individual HCoV S-expression
plasmids. All four non-SARS-related S proteins showed
band sizes that were consistent with the predicted molecu-
lar mass (150–200 kDa), presumably reflecting glycosyl-
ated forms of S protein. In addition, the expression of
Figure 1 Construction and characterization of spike expression plasmids derived from non-SARS HCoVs. (A) Construction scheme of spike
(S) fragment expression plasmids derived from four individual HCoVs (−229E, -OC43, -NL63, and -HKU1). (B) Characterisation of S proteins of individual
HCoV expression plasmids by western blot using anti-S mouse serum from DNA vaccination. Forty-eight hours after 293 T cell transfection with the
above individual HCoV expression plasmids, the cell lysates were collected for SDS-PAGE and western blot. (C) Characterisation of S protein by indirect
immune fluorescence assay (IFA) using anti-S serum from mice immunised with individual HCoV expression plasmids. The control was transfected with
pVRC-8303 plasmid and detected with mixed anti-S mouse serum of a non-SARS CoV.
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recombinant HCoV S proteins was further confirmed
by immunofluorescence staining using specific anti-S
mouse serum, as noted above (Figure 1C). All S proteins
were expressed mainly in the cytoplasm and membrane.
No cross-staining was observed when other HCoV anti-
serum was used as the primary antibody, specifically
concerning virus-antibody pairs of subgroup 229E/NL63
(alphacoronaviruses) or OC43/HKU1(batacoronaviruses).
Furthermore, no false positive/negative result was ob-
served in our study (data not shown).
Prevalence of anti-S IgG according to age group
A representative anti-S-positive IFA result is shown in
Figure 2. Using IFA based on 293FT cells expressing individ-
ual S proteins of HCoV, we investigated the seroprevalence
of these viruses in serum from various age groups of
a healthy population in Beijing. All samples were
tested three using IFA and the result showed well
reproducibility.
Of 794 serum samples tested for anti-S IgG by IFA, only
29 (3.65%) were negative for anti-S IgG of HCoV (Table 1).
665 (83.75%) serum samples were positive for HCoV-
229E, 580 (73.05%) for HCoV-NL63, 590 (74.31%) for
HCoV-OC43, and 549 (69.14%) for HCoV-HKU1. There
were no significant differences between genders.
The distribution and variation trend of anti-S IgG to the
four HCoVs among the age groups are shown in Figure 3.
The seropositivity rate was 70.15% for HCoV-229E and
62.69% for HCoV-OC43, which are similar to the levels of
HCoV-HKU1 (58.21%) and HCoV-NL63 (60%) among the
1- to 3-year-old group (p > 0.05). The proportions of
HCoV IgG-positive samples increased with age during in-
fancy, reaching levels >75% at age >4 years. Interesting, a
significant drop in seropositivity rate was observed for
HCoV-OC43 in the 15- to 30-year-old group and for
HCoV-HKU1 in the 7- to 14-year-old group. In the
child population (n = 218), the total positivity rate of
anti-S IgG antibodies was 73.85% for 229E, 68.81%
for OC43, 61.93% for HKU1, and 66.51% for NL63
(Figure 3); no significant differences were observed with
regard to IgG to two novel HCoVs among the children
(NL63, p = 0.051; HKU1, p = 0.329).
In the adult population (≥14 years of age), the seropreva-
lence of anti-S IgG of HCoV-229E, -OC43, and -NL-63
did not differ significantly among the age groups (229E,
p = 0.323; NL63, p = 0.545; OC43, p = 0.204). For HCoV-
HKU1, a significant increase in the seroprevalence rate
with increasing age was observed (p = 0.025). In the
adult population (n = 576), the IgG positivity rate was
87.5% for 229E, 76.39% for OC43, 71.88% for HKU1,
and 75.52% for NL63. The proportion of subjects with
detectable IgG antibodies to HCoV-229E was signifi-
cantly greater than that to -OC43 and -NL63 (p < 0.05).
Furthermore, the number of subjects with IgG to the
three above-mentioned HCoVs was also significantly
greater than that to HCoV-HKU1 (p < 0.05). However,
there were no significant differences in the anti-S IgG
Table 1 Demographic characteristics and anti-S IgG
detection of the study subjects
Characteristic Value (male/female) %
No. of subjects 794 (457/337)
Mean age (y) 28.75 ± 17.79
Age range (y) 0.5–75
Group
Child (<14 y) 215 (113/102)
<1 y 8 (5/3)
1–3 y 134 (68/66)
3–6 y 46 (28/18)
7–14 y 27 (12/15)
Adult (≥14 y) 579 (344/235)
15–30 y 150 (76/74)
31–40 y 211 (132/79)
41–50 y 152 (91/61)
≥51 y 66 (45/21)




All (−) 29 3.65
Figure 2 Representative IFA for detection of anti-S antibodies of non-SARS HCoVs in human serum. A, 229E-S expression plasmid;
B, OC43-S expression plasmid; C, HKU1-S expression plasmid; D, NL63-S expression plasmid; control, mock plasmid pVRC-8304.
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seropositivity rates of individual HCoVs with respect to
gender in either the child or adult population (Data not
shown).
Anti-S IgM detection in children
The prevalence and variation trend of anti-S IgM anti-
bodies to individual HCoVs among the child population
is shown in Figure 4. The total positivity rate of anti-S
IgM was 36.24% for 229E, 43.12% for OC43, 54.46% for
HKU1, and 44.50% for NL63. The anti-S IgM positivity
rate of HCoV-229E was significantly lower than that of
the other three HCoVs (p = 0.028), while there were no
significant differences in the anti-S IgM seropositivity
rates of individual HCoVs with respect to gender (Data
not shown).
There was a significant difference in the anti-S IgM
positivity rate for individual HCoVs among age groups.
The anti-S IgM positivity rate of HCoV-HKU1 was sig-
nificantly higher than that of the other three HCoVs
among the < 3-year-old groups (Figure 4). The positivity
rate increased with age and began to drop after peaking
in the school-age group (≥6 years), which is similar to
that described above for anti-S IgG detection. No anti-S
IgM antibodies for the four individual HCoVs were
detected in the serum of the healthy adult population
>15 years of age.
Discussion
This is the first comprehensive study to evaluate anti-S IgG
and IgM for four non-SARS HCoVs among the general
population in China. We first time show that anti-S IgM is
only present in children, indicating that for all viruses first
infection takes place during childhood (age < 14 years).
The SARS epidemic that originated from southern China
in 2003 sparked interest in all areas of coronavirus research
[4-9]. Four endemic non-SARS-related HCoVs (HCoV-
OC43,-229E,-NL63 and –HKU1) are major contributors to
respiratory tract infections and other clinical manifesta-
tions [6,11-17,22]. However, specific and feasible sero-
logical surveys of these HCoVs, especially for HCoV-NL63
Figure 3 Anti-S IgG positivity rate of individual HCoVs according to age group. (A) Anti-S IgG positivity rates for HCoV-229E; (B) Anti-S IgG
positivity rates for HCoV-OC43; (C) Anti-S IgG positivity rates for HCoV-HKU1; (D) Anti-S IgG positivity rates for HCoV-NL63.
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and –HKU1, have to date been reported among the general
population only rarely in China. Spike is the major struc-
tural protein of HCoVs [1,10]. It contains multiple con-
formational epitopes that are major inducers of antibody
neutralisation, and it has the lowest sequence conservation
among coronavirus proteins, rendering it a specific target
for serodiagnosis [1,10,23-26]. We chose the HCoV S gene
for recombinant expression on the basis of current know-
ledge of immunodominant SARS-CoV antigens, which be-
longs to the same virus family as HCoV. Previous studies
of SARS-CoV serology have successfully used the S protein
in enzyme immunoassays, immunoblots, and IFA [23-27].
In addition, comparison of the S protein sequences of four
HCoVs revealed that these proteins share <35% similarity
[1,10]. We hypothesised that the difference in the amino
acid sequence is sufficiently high to ensure the usefulness
of S protein as a specific antigen for antibody detection.
The native surface S protein expressed in 293 T cells can
be recognised in post-infection population serum by IFA.
Some reports indicated that this cell-based S protein
expression system can differentiate false-positive ELISA
results using the more cross-reactive nucleoprotein antigen
[18,24]. Furthermore, Woo et al. reported that the rS-
based IgM ELISA is more sensitive than the rN-based IgM
ELISA for SARS-CoV pneumonia [25]. Our results showed
that the S-based IFA enabled specific detection of IgG or
IgM to four individual HCoVs.
Using IFA, we investigated the natural seroprevalence of
four non-SARS-related HCoVs in blood samples from a
general population that comprised a variety of age groups.
Anti-S IgG antibodies to these four non-SARS-related
HCoVs were detected at high rates (>70%) among healthy
adults. Both anti-S IgG and IgM antibodies were found in
the child group, and their prevalence increased with age
up to 6 years, at which point it almost plateaued. These
data suggest that exposure to HCoV is common in child-
hood and first infections by all four non-SARS HCoVs
takes place during children. Moreover, we found evidence
of anti-S IgG against double and multiple HCoVs in vari-
ous combinations, which indicates that large proportions
of the general population in Beijing may experience infec-
tions with more than one HCoV.
Figure 4 Anti-S IgM positivity rates of individual HCoVs according to age group. (A) Anti-S IgM positivity rates for HCoV-229E;
(B) Anti-S IgM positivity rates for HCoV-OC43; (C) Anti-S IgM positivity rates for HCoV-NL63. (D) Anti-S IgM positivity rates for HCoV-HKU1.
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The seroprevalence of HCoV antibodies varies widely
among studies, which used different antigens and meth-
odologies [6,13-18,26-33]. Previous studies of non-SARS
HCoVs demonstrated that seroprevalence varies greatly
depending on the age of the population [6,13-18,26-33].
Our IFA study showed that the prevalence of the four
anti-S IgG antibodies among this general Chinese popu-
lation were slightly higher than those in another study
from Germany using an Escherichia coli BL21-expressed
recombinant N-based line immunoassay [13], which
reported that the seropositivities in 25 healthy blood do-
nors were 48% for HCoV-HKU1, 52% for -OC43, 56%
for -229E, and 60% for -NL63. On the other hand, the
seropositivity rate of three individual HCoVs excluding
HCoV-HKU1 in this study was lower than that in an-
other study of a US metropolitan adult population using
baculovirus-expressed recombinant N-based ELISA [14],
which showed seropositivity rates of 90.8% for HCoV-
OC43, 91.3% for -229E, and 91.8% for -NL63, while that
for -HKU1 was 59.2%. It was also supposed that the sig-
nificantly different seropositivity rates for the various
HCoVs might result in individuals with different demo-
graphic factors (e.g. ethnicity, smoking status, and so-
cioeconomic status) having different susceptibilities to
individual HCoVs [14]. A recent study of 105 older adult
veterans with underlying chronic obstructive pulmonary
disease at seven US sites showed that serum IgG to
HCoV-229E, -NL63, and -OC43 was detected in at least
98% of subjects, while antibodies to -HKU1 were identi-
fied in 96 subjects (91%) [17]. Thus EIA assays that use
whole virus or N protein as the antigen, using which ap-
parent cross-reactivity of HCoV antibodies has been
demonstrated previously [18,24], may detect group- ra-
ther than type-specific antibody.
Our results regarding anti-S IgG to four individual
HCoVs in children correlate with those of previous sero-
prevalence studies [6,13-18,26-33], although the data on
HCoV-NL63 and -HKU1 were limited. Shao et al. found
that antibodies directed to HCoV-NL63 and -229E in
children 1 year of age and older were frequently detected
using part of the C-terminal region of the N protein as
an antibody capture antigen in an ELISA [15]. A study
of children in the Netherlands aged 2.5–3.5 years indi-
cated that 75% and 65% of serum samples were positive
for antibodies to HCoV-NL63 and -229E, respectively
[16]. We observed that the prevalence of these four non-
SARS-related HCoV-directed IgG antibodies among
children >1 year of age were almost identical.
Information on the prevalence of anti-S IgM to non-
SARS-related HCoV is to-date lacking. We first investi-
gated the prevalence of anti-S IgM to four individual
HCoVs among a general population in Beijing using IFA.
Anti-S IgM to individual HCoVs was detected in a por-
tion of the asymptomatic child population. The anti-S
IgM seropositivity appeared to increase with age up to
6 years and decline sharply after 14 years of age. How-
ever, no anti-S IgM to individual HCoVs was detected in
the healthy adult population. These results suggest that
primary seroconversion to these viruses occurs mainly
during childhood and youth; In addition, HCoV infec-
tion might result in seroconversion in children with
asymptomatic or subclinical manifestations. These re-
sults are also in agreement with HCoV molecular epi-
demiological surveys [12,34], which have indicated that
primary exposure occurs mainly in childhood and youth.
Conclusion
We conclude that S-based IFA might be a useful specific
serological platform for epidemiologic investigation of
HCoV infection. High proportions of children and adults
in Beijing show anti-S IgG seropositivity against the four
HCoVs, and anti-S IgM antibodies were detected in the
sera of asymptomatic children. These four non-SARS-
related HCoVs appear be circulating in the general popula-
tion, and sustained HCoV infection becomes more likely
with increasing age. This study may serve as a basis for the
prevention and control of non-SARS-related HCoV infec-
tion. However, further research is needed to determine the
false-positivity and -negativity rates associated with this
anti-S IFA by determining antibody titres during the acute
and convalescent phases after primary HCoV infection.
Comparison of serological methods and antigen prepara-
tions as well as sample exchange will facilitate validation
of the assays for individual HCoV antibody determination.
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